Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
5°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
181.77
-1.16 (-0.63%)
Official Closing Price
Updated: 7:00 PM EST, Dec 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
October 06, 2024
Declining earnings haven't scared billionaire investors away from this stock.
Via
The Motley Fool
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
October 05, 2024
These companies can lend growth and dividend returns to a long-term investor's portfolio.
Via
The Motley Fool
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
October 04, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
3 Industries Set To Explode When Interest Rates Drop
October 03, 2024
Via
Talk Markets
Comparing AbbVie With Industry Competitors In Biotechnology Industry
October 03, 2024
Via
Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
October 03, 2024
Via
Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
September 27, 2024
Via
Benzinga
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
October 03, 2024
Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025.
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
5 Best Dividend Growth Stocks to Buy in October
October 02, 2024
These five stocks are known for their generous dividend programs and robust business models.
Via
The Motley Fool
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
September 26, 2024
Via
Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
September 30, 2024
On CNBC's "Halftime Report Final Trades," Kevin Simpson of Capital Wealth Planning said Meta Platforms is hitting on all cylinders.
Via
Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
September 30, 2024
These 15 dividend stocks can deliver stable passive income for life.
Via
The Motley Fool
Behind the Scenes of AbbVie's Latest Options Trends
September 24, 2024
Via
Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
September 20, 2024
Via
Benzinga
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
September 19, 2024
Via
Benzinga
Is ABBVIE INC Ready to Break Out of Its Range?
September 17, 2024
Interesting Technical Analysis finding for ABBVIE INC (NYSE:ABBV)
Via
Chartmill
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for...
Via
Benzinga
Exposures
Product Safety
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
September 26, 2024
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and...
Via
Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
September 26, 2024
Even the mighty Novo Nordisk can't hold a candle to its peer in this area.
Via
The Motley Fool
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
September 20, 2024
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental...
Via
Benzinga
Exposures
Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
September 19, 2024
For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18,
September 18, 2024
Looking for upside into wave {v} as we are trading within the parallel channel where we could eventually seek for support within wave {iv}.
Via
Talk Markets
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
September 17, 2024
TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as top trades on CNBC's Halftime Report.
Via
Benzinga
Topics
ETFs
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
September 16, 2024
The dividend growth powerhouse is turning the corner.
Via
The Motley Fool
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
September 14, 2024
Financial factors aren't the only things that are worth paying attention to.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.